{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:13:51Z","timestamp":1784290431027,"version":"3.55.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,9,29]],"date-time":"2012-09-29T00:00:00Z","timestamp":1348876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s40291-012-0006-3","type":"journal-article","created":{"date-parts":[[2012,9,30]],"date-time":"2012-09-30T13:18:31Z","timestamp":1349011111000},"page":"269-283","source":"Crossref","is-referenced-by-count":16,"title":["Current Outlook on Molecular Pathogenesis and Treatment of Myeloproliferative Neoplasms"],"prefix":"10.1007","volume":"16","author":[{"given":"Raoul","family":"Tibes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Bogenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasey L.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,29]]},"reference":[{"key":"6_CR1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"6_CR2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","volume":"93","author":"F Passamonti","year":"2008","unstructured":"Passamonti F, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93:1645\u201351.","journal-title":"Haematologica"},{"key":"6_CR3","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C","volume":"67","author":"C Rozman","year":"1991","unstructured":"Rozman C, et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991;67:2658\u201363.","journal-title":"Cancer"},{"key":"6_CR4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4065\/76.1.22","volume":"76","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, et al. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001;76:22\u20138.","journal-title":"Mayo Clin Proc"},{"key":"6_CR5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114\u201324.","journal-title":"N Engl J Med"},{"key":"6_CR6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","volume":"136","author":"M Nisio Di","year":"2007","unstructured":"Di Nisio M, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136:249\u201359.","journal-title":"Br J Haematol"},{"key":"6_CR7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33\u201345.","journal-title":"N Engl J Med"},{"key":"6_CR8","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065\u201372.","journal-title":"Blood"},{"key":"6_CR9","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895\u2013901.","journal-title":"Blood"},{"key":"6_CR10","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1182\/blood-2009-02-195974","volume":"113","author":"RA Mesa","year":"2009","unstructured":"Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood. 2009;113:5394\u2013400.","journal-title":"Blood"},{"key":"6_CR11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood-2011-01-327213","volume":"118","author":"R Tibes","year":"2011","unstructured":"Tibes R, Mesa RA. Blood consult: resistant and progressive essential thrombocythemia. Blood. 2011;118:240\u20132.","journal-title":"Blood"},{"key":"6_CR12","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/1042819021000040008","volume":"43","author":"G Barosi","year":"2002","unstructured":"Barosi G, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma. 2002;43:2301\u20137.","journal-title":"Leuk Lymphoma"},{"key":"6_CR13","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","volume":"101","author":"RA Mesa","year":"2003","unstructured":"Mesa RA, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101:2534\u201341.","journal-title":"Blood"},{"key":"6_CR14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2141.2005.05524.x","volume":"129","author":"F Cervantes","year":"2005","unstructured":"Cervantes F, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol. 2005;129:771\u20135.","journal-title":"Br J Haematol"},{"key":"6_CR15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0609.1990.tb00344.x","volume":"44","author":"E Lofvenberg","year":"1990","unstructured":"Lofvenberg E, et al. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol. 1990;44:33\u20138.","journal-title":"Eur J Haematol"},{"key":"6_CR16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.0007-1048.2001.03331.x","volume":"116","author":"MC Petti","year":"2002","unstructured":"Petti MC, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;116:576\u201381.","journal-title":"Br J Haematol"},{"key":"6_CR17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","volume":"107","author":"RA Mesa","year":"2006","unstructured":"Mesa RA, et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107:361\u201370.","journal-title":"Cancer"},{"key":"6_CR18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2141.1998.00998.x","volume":"103","author":"MA Elliott","year":"1998","unstructured":"Elliott MA, et al. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 1998;103:505\u201311.","journal-title":"Br J Haematol"},{"key":"6_CR19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","volume":"16","author":"KK Ballen","year":"2010","unstructured":"Ballen KK, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transpl. 2010;16:358\u201367.","journal-title":"Biol Blood Marrow Transpl"},{"key":"6_CR20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392\u20137.","journal-title":"J Clin Oncol"},{"key":"6_CR21","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703\u20138.","journal-title":"Blood"},{"key":"6_CR22","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","volume":"27","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418\u201324.","journal-title":"J Clin Oncol"},{"key":"6_CR23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.V93.2.417","volume":"93","author":"CN Harrison","year":"1999","unstructured":"Harrison CN, et al. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 1999;93:417\u201324.","journal-title":"Blood"},{"key":"6_CR24","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128\u201338.","journal-title":"Leukemia"},{"key":"6_CR25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3322\/caac.20009","volume":"59","author":"AM Vannucchi","year":"2009","unstructured":"Vannucchi AM, et al. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59:171\u201391.","journal-title":"CA Cancer J Clin"},{"key":"6_CR26","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"6_CR27","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20138.","journal-title":"Nature"},{"key":"6_CR28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell"},{"key":"6_CR29","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","volume":"280","author":"R Zhao","year":"2005","unstructured":"Zhao R, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788\u201392.","journal-title":"J Biol Chem"},{"key":"6_CR30","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u201390.","journal-title":"N Engl J Med"},{"key":"6_CR31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","volume":"131","author":"AP Wolanskyj","year":"2005","unstructured":"Wolanskyj AP, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005;131:208\u201313.","journal-title":"Br J Haematol"},{"key":"6_CR32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s12185-010-0596-7","volume":"91","author":"J Trelinski","year":"2010","unstructured":"Trelinski J, et al. Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. Int J Hematol. 2010;91:792\u20138.","journal-title":"Int J Hematol"},{"key":"6_CR33","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1172\/JCI110546","volume":"69","author":"RC Ash","year":"1982","unstructured":"Ash RC, et al. In vitro studies of human pluripotential hematopoietic progenitors in polycythemia vera: direct evidence of stem cell involvement. J Clin Invest. 1982;69:1112\u20138.","journal-title":"J Clin Invest"},{"key":"6_CR34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1172\/JCI115009","volume":"87","author":"CH Dai","year":"1991","unstructured":"Dai CH, et al. Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3. J Clin Invest. 1991;87:391\u20136.","journal-title":"J Clin Invest"},{"key":"6_CR35","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1182\/blood.V96.10.3310","volume":"96","author":"AA Axelrad","year":"2000","unstructured":"Axelrad AA, et al. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood. 2000;96:3310\u201321.","journal-title":"Blood"},{"key":"6_CR36","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","volume":"106","author":"J Jelinek","year":"2005","unstructured":"Jelinek J, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370\u20133.","journal-title":"Blood"},{"key":"6_CR37","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","volume":"106","author":"DP Steensma","year":"2005","unstructured":"Steensma DP, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207\u20139.","journal-title":"Blood"},{"key":"6_CR38","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","volume":"106","author":"LM Scott","year":"2005","unstructured":"Scott LM, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood. 2005;106:2920\u20131.","journal-title":"Blood"},{"key":"6_CR39","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","volume":"115","author":"PA Beer","year":"2010","unstructured":"Beer PA, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115:2891\u2013900.","journal-title":"Blood"},{"key":"6_CR40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","volume":"106","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer. 2006;106:631\u20135.","journal-title":"Cancer"},{"key":"6_CR41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0609.2007.00960.x","volume":"79","author":"TS Larsen","year":"2007","unstructured":"Larsen TS, et al. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis\u2014impact on disease phenotype. Eur J Haematol. 2007;79:508\u201315.","journal-title":"Eur J Haematol"},{"key":"6_CR42","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","volume":"22","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, et al. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22:1299\u2013307.","journal-title":"Leukemia"},{"key":"6_CR43","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","volume":"107","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006;107:2098\u2013100.","journal-title":"Blood"},{"key":"6_CR44","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","volume":"114","author":"P Guglielmelli","year":"2009","unstructured":"Guglielmelli P, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009;114:1477\u201383.","journal-title":"Blood"},{"key":"6_CR45","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","volume":"109","author":"J Kittur","year":"2007","unstructured":"Kittur J, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007;109:2279\u201384.","journal-title":"Cancer"},{"key":"6_CR46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/10428190802688152","volume":"50","author":"F Palandri","year":"2009","unstructured":"Palandri F, et al. JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. Leuk Lymphoma. 2009;50:247\u201353.","journal-title":"Leuk Lymphoma"},{"key":"6_CR47","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","volume":"21","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21:1952\u20139.","journal-title":"Leukemia"},{"key":"6_CR48","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459\u201368.","journal-title":"N Engl J Med"},{"key":"6_CR49","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani A, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007;21:1960\u20133.","journal-title":"Leukemia"},{"key":"6_CR50","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437\u20138.","journal-title":"Leukemia"},{"key":"6_CR51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","volume":"93","author":"E Antonioli","year":"2008","unstructured":"Antonioli E, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008;93:41\u20138.","journal-title":"Haematologica"},{"key":"6_CR52","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","volume":"41","author":"D Olcaydu","year":"2009","unstructured":"Olcaydu D, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41:450\u20134.","journal-title":"Nat Genet"},{"key":"6_CR53","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","volume":"41","author":"AV Jones","year":"2009","unstructured":"Jones AV, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41:446\u20139.","journal-title":"Nat Genet"},{"key":"6_CR54","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1600-0609.2010.01428.x","volume":"84","author":"MM Patnaik","year":"2010","unstructured":"Patnaik MM, et al. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. Eur J Haematol. 2010;84:518\u201324.","journal-title":"Eur J Haematol"},{"key":"6_CR55","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/leu.2008.226","volume":"22","author":"H Quentmeier","year":"2008","unstructured":"Quentmeier H, et al. SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia. 2008;22:2169\u201375.","journal-title":"Leukemia"},{"key":"6_CR56","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/leu.2010.99","volume":"24","author":"R Jager","year":"2010","unstructured":"Jager R, et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia. 2010;24:1290\u20138.","journal-title":"Leukemia"},{"key":"6_CR57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","volume":"118","author":"T Klampfl","year":"2011","unstructured":"Klampfl T, et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood. 2011;118:167\u201376.","journal-title":"Blood"},{"key":"6_CR58","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","volume":"117","author":"F Passamonti","year":"2011","unstructured":"Passamonti F, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011;117:2813\u20136.","journal-title":"Blood"},{"key":"6_CR59","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.22063","volume":"86","author":"LM Scott","year":"2011","unstructured":"Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol. 2011;86:668\u201376.","journal-title":"Am J Hematol"},{"key":"6_CR60","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472\u20136.","journal-title":"Blood"},{"key":"6_CR61","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.","journal-title":"PLoS Med"},{"key":"6_CR62","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2141.2006.06348.x","volume":"135","author":"TL Lasho","year":"2006","unstructured":"Lasho TL, et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol. 2006;135:683\u20137.","journal-title":"Br J Haematol"},{"issue":"11","key":"6_CR63","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood.V112.11.3714.3714","volume":"112","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, et al. Constitutively activated and hyper-sensitive basophils in patients with polycythemia vera: role of JAK2V617F mutation and correlation with pruritus [abstract no. 3714]. Blood. 2008;112(11):3714.","journal-title":"Blood"},{"key":"6_CR64","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","volume":"112","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, et al. Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia. Blood. 2008;112:844\u20137.","journal-title":"Blood"},{"key":"6_CR65","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","volume":"137","author":"P Guglielmelli","year":"2007","unstructured":"Guglielmelli P, et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol. 2007;137:244\u20137.","journal-title":"Br J Haematol"},{"key":"6_CR66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","volume":"112","author":"PA Beer","year":"2008","unstructured":"Beer PA, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141\u20139.","journal-title":"Blood"},{"key":"6_CR67","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","volume":"116","author":"ST Oh","year":"2010","unstructured":"Oh ST, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116:988\u201392.","journal-title":"Blood"},{"key":"6_CR68","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1084\/jem.20011883","volume":"195","author":"L Velazquez","year":"2002","unstructured":"Velazquez L, et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med. 2002;195:1599\u2013611.","journal-title":"J Exp Med"},{"key":"6_CR69","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1182\/blood-2009-12-256768","volume":"116","author":"F Baran-Marszak","year":"2010","unstructured":"Baran-Marszak F, et al. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood. 2010;116:5961\u201371.","journal-title":"Blood"},{"key":"6_CR70","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","volume":"460","author":"M Sanada","year":"2009","unstructured":"Sanada M, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009;460:904\u20138.","journal-title":"Nature"},{"key":"6_CR71","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","volume":"114","author":"ML Loh","year":"2009","unstructured":"Loh ML, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 2009;114:1859\u201363.","journal-title":"Blood"},{"key":"6_CR72","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1200\/JCO.2009.23.7503","volume":"27","author":"H Makishima","year":"2009","unstructured":"Makishima H, et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol. 2009;27:6109\u201316.","journal-title":"J Clin Oncol"},{"key":"6_CR73","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","volume":"113","author":"FH Grand","year":"2009","unstructured":"Grand FH, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113:6182\u201392.","journal-title":"Blood"},{"key":"6_CR74","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","volume":"118","author":"AM Jankowska","year":"2011","unstructured":"Jankowska AM, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118:3932\u201341.","journal-title":"Blood"},{"key":"6_CR75","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","volume":"361","author":"ER Mardis","year":"2009","unstructured":"Mardis ER, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058\u201366.","journal-title":"N Engl J Med"},{"key":"6_CR76","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553\u201367.","journal-title":"Cancer Cell"},{"key":"6_CR77","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","volume":"483","author":"C Lu","year":"2012","unstructured":"Lu C, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483:474\u20138.","journal-title":"Nature"},{"key":"6_CR78","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMc0910063","volume":"362","author":"A Green","year":"2010","unstructured":"Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010;362:369\u201370.","journal-title":"N Engl J Med"},{"key":"6_CR79","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","volume":"24","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010;24:1713\u20138.","journal-title":"Leukemia"},{"key":"6_CR80","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010;24:1302\u20139.","journal-title":"Leukemia"},{"key":"6_CR81","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","volume":"468","author":"M Ko","year":"2010","unstructured":"Ko M, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468:839\u201343.","journal-title":"Nature"},{"key":"6_CR82","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1182\/blood-2010-12-325241","volume":"118","author":"Z Li","year":"2011","unstructured":"Li Z, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011;118:4509\u201318.","journal-title":"Blood"},{"key":"6_CR83","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2009","unstructured":"Delhommeau F, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289\u2013301.","journal-title":"N Engl J Med"},{"key":"6_CR84","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/leu.2009.59","volume":"23","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS\/MPN and AML. Leukemia. 2009;23:1343\u20135.","journal-title":"Leukemia"},{"key":"6_CR85","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2009.011205","volume":"94","author":"O Kosmider","year":"2009","unstructured":"Kosmider O, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94:1676\u201381.","journal-title":"Haematologica"},{"key":"6_CR86","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1182\/blood-2009-02-205690","volume":"113","author":"AM Jankowska","year":"2009","unstructured":"Jankowska AM, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic\/myeloproliferative neoplasms. Blood. 2009;113:6403\u201310.","journal-title":"Blood"},{"key":"6_CR87","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","volume":"23","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23:905\u201311.","journal-title":"Leukemia"},{"key":"6_CR88","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1182\/blood-2009-04-215814","volume":"114","author":"O Kosmider","year":"2009","unstructured":"Kosmider O, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114:3285\u201391.","journal-title":"Blood"},{"key":"6_CR89","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496\u2013506.","journal-title":"N Engl J Med"},{"key":"6_CR90","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2009-03-210039","volume":"114","author":"O Abdel-Wahab","year":"2009","unstructured":"Abdel-Wahab O, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114:144\u20137.","journal-title":"Blood"},{"key":"6_CR91","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","volume":"28","author":"A Kohlmann","year":"2010","unstructured":"Kohlmann A, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28:3858\u201365.","journal-title":"J Clin Oncol"},{"key":"6_CR92","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0378-1119(03)00430-X","volume":"306","author":"CL Fisher","year":"2003","unstructured":"Fisher CL, et al. A human homolog of Additional sex combs, ADDITIONAL SEX COMBS-LIKE 1, maps to chromosome 20q11. Gene. 2003;306:115\u201326.","journal-title":"Gene"},{"key":"6_CR93","doi-asserted-by":"crossref","first-page":"17588","DOI":"10.1074\/jbc.M512616200","volume":"281","author":"YS Cho","year":"2006","unstructured":"Cho YS, et al. Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem. 2006;281:17588\u201398.","journal-title":"J Biol Chem"},{"key":"6_CR94","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","volume":"23","author":"N Carbuccia","year":"2009","unstructured":"Carbuccia N, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23:2183\u20136.","journal-title":"Leukemia"},{"key":"6_CR95","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3324\/haematol.2011.045591","volume":"96","author":"BL Stein","year":"2011","unstructured":"Stein BL, et al. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica. 2011;96:1462\u20139.","journal-title":"Haematologica"},{"key":"6_CR96","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","volume":"151","author":"V Gelsi-Boyer","year":"2010","unstructured":"Gelsi-Boyer V, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151:365\u201375.","journal-title":"Br J Haematol"},{"issue":"8","key":"6_CR97","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/gcc.21960","volume":"51","author":"M Brecqueville","year":"2012","unstructured":"Brecqueville M, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer. 2012;51(8):743\u201355.","journal-title":"Genes Chromosomes Cancer"},{"key":"6_CR98","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","volume":"25","author":"O Abdel-Wahab","year":"2011","unstructured":"Abdel-Wahab O, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011;25:1200\u20132.","journal-title":"Leukemia"},{"key":"6_CR99","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424\u201333.","journal-title":"N Engl J Med"},{"key":"6_CR100","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2011.77","volume":"25","author":"F Stegelmann","year":"2011","unstructured":"Stegelmann F, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia. 2011;25:1217\u20139.","journal-title":"Leukemia"},{"key":"6_CR101","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","volume":"118","author":"P Guglielmelli","year":"2011","unstructured":"Guglielmelli P, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood. 2011;118:5227\u201334.","journal-title":"Blood"},{"key":"6_CR102","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","volume":"453","author":"CG Mullighan","year":"2008","unstructured":"Mullighan CG, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110\u20134.","journal-title":"Nature"},{"key":"6_CR103","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64\u20139.","journal-title":"Nature"},{"key":"6_CR104","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384\u201395.","journal-title":"N Engl J Med"},{"key":"6_CR105","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","volume":"119","author":"SJ Zhang","year":"2012","unstructured":"Zhang SJ, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012;119:4480\u20135.","journal-title":"Blood"},{"key":"6_CR106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/asheducation-2010.1.115","volume":"2010","author":"RA Mesa","year":"2010","unstructured":"Mesa RA. Assessing new therapies and their overall impact in myelofibrosis. Hematol Am Soc Hematol Educ Program. 2010;2010:115\u201321.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"6_CR107","doi-asserted-by":"crossref","unstructured":"Tibes R, Mesa RA. JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data. Clin Investig. 2011;1(12):1681\u201393. http:\/\/www.future-science.com\/doi\/abs\/10.4155\/cli.11.124 . Accessed 2012 Sep 6.","DOI":"10.4155\/cli.11.124"},{"issue":"21","key":"6_CR108","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1182\/blood.V116.21.4087.4087","volume":"116","author":"L Ma","year":"2010","unstructured":"Ma L, et al. Efficacy of LY2784544, a small molecule inhibitor selective for mutant JAK2 kinase, in JAK2 V617F-induced hematologic malignancy models [abstract no. 4087]. Blood. 2010;116(21):4087.","journal-title":"Blood"},{"key":"6_CR109","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115:3109\u201317.","journal-title":"Blood"},{"key":"6_CR110","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117\u201327.","journal-title":"N Engl J Med"},{"key":"6_CR111","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807.","journal-title":"N Engl J Med"},{"key":"6_CR112","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398.","journal-title":"N Engl J Med"},{"key":"6_CR113","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","volume":"13","author":"G Wernig","year":"2008","unstructured":"Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13:311\u201320.","journal-title":"Cancer Cell"},{"key":"6_CR114","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29:789\u201396.","journal-title":"J Clin Oncol"},{"issue":"21","key":"6_CR115","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V116.21.3082.3082","volume":"116","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, et al. Phase 1\/2 study of SB1518, a novel JAK2\/FLT3 inhibitor, in the treatment of primary myelofibrosis [abstract no. 3082]. Blood. 2010;116(21):3082.","journal-title":"Blood"},{"issue":"15 Suppl.","key":"6_CR116","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1200\/jco.2011.29.15_suppl.6515","volume":"29","author":"H Deeg","year":"2011","unstructured":"Deeg H, et al. Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis [abstract no. 6515]. J Clin Oncol. 2011;29(15 Suppl.):6515.","journal-title":"J Clin Oncol"},{"issue":"21","key":"6_CR117","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood.V118.21.282.282","volume":"118","author":"RS Komrokji","year":"2011","unstructured":"Komrokji RS, et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis [abstract no. 282]. Blood. 2011;118(21):282.","journal-title":"Blood"},{"key":"6_CR118","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","volume":"33","author":"RA Mesa","year":"2009","unstructured":"Mesa RA, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33:1199\u2013203.","journal-title":"Leuk Res"},{"key":"6_CR119","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","volume":"115","author":"JW Tyner","year":"2010","unstructured":"Tyner JW, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010;115:5232\u201340.","journal-title":"Blood"},{"key":"6_CR120","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","volume":"115","author":"FP Santos","year":"2010","unstructured":"Santos FP, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis. Blood. 2010;115:1131\u20136.","journal-title":"Blood"},{"issue":"21","key":"6_CR121","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/blood.V118.21.2814.2814","volume":"118","author":"S Verstovsek","year":"2011","unstructured":"Verstovsek S, et al. Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) [abstract no. 2814]. Blood. 2011;118(21):2814.","journal-title":"Blood"},{"key":"6_CR122","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccr.2009.10.015","volume":"16","author":"M Hedvat","year":"2009","unstructured":"Hedvat M, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009;16:487\u201397.","journal-title":"Cancer Cell"},{"issue":"22","key":"6_CR123","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1182\/blood.V114.22.3897.3897","volume":"114","author":"K Shide","year":"2009","unstructured":"Shide K, et al. Efficacy of R723, a potent and selective JAK2 inhibitor, in JAK2V617F-induced murine MPD model [abstract no. 3897]. Blood. 2009;114(22):3897.","journal-title":"Blood"},{"issue":"21","key":"6_CR124","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1182\/blood.V116.21.4112.4112","volume":"116","author":"AV Purandare","year":"2010","unstructured":"Purandare AV, et al. Characterization of BMS-911543, a functionally selective small molecule inhibitor of JAK2 [abstract no. 4112]. Blood. 2010;116(21):4112.","journal-title":"Blood"},{"issue":"21","key":"6_CR125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.V116.21.313.313","volume":"116","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, et al. Durable responses with the JAK1\/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU) [abstract no. 313]. Blood. 2010;116(21):313.","journal-title":"Blood"},{"key":"6_CR126","doi-asserted-by":"crossref","unstructured":"Verstovsek S, et al. RESPONSE: a randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU) [abstract no. TPS203]. J Clin Oncol. 2011;29(Suppl.):TPS203.","DOI":"10.1200\/jco.2011.29.15_suppl.tps203"},{"key":"6_CR127","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","volume":"22","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, et al. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008;22:1990\u20138.","journal-title":"Leukemia"},{"key":"6_CR128","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","volume":"117","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, et al. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117:4706\u201315.","journal-title":"Blood"},{"issue":"21","key":"6_CR129","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1182\/blood.V116.21.314.314","volume":"116","author":"AM Vannucchi","year":"2010","unstructured":"Vannucchi AM, et al. A phase 1\/2 study of RAD001, a mTOR inhibitor, in patients with myelofibrosis: final results [abstract no. 314]. Blood. 2010;116(21):314.","journal-title":"Blood"},{"issue":"22","key":"6_CR130","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood.V114.22.308.308","volume":"114","author":"J Mascarenhas","year":"2009","unstructured":"Mascarenhas J, et al. A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia\/essential thrombocythemia myelofibrosis (post-PV\/ET MF). Blood. 2009;114(22):308.","journal-title":"Blood"},{"key":"6_CR131","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","volume":"150","author":"A Rambaldi","year":"2010","unstructured":"Rambaldi A, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150:446\u201355.","journal-title":"Br J Haematol"},{"issue":"21","key":"6_CR132","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1182\/blood.V118.21.1748.1748","volume":"118","author":"A Rambaldi","year":"2011","unstructured":"Rambaldi A, et al. A phase II study of the HDAC inhibitor givinostat in combination with hydroxyurea in patients with polycythemia vera resistant to hydroxyurea monotherapy [abstract no. 1748]. Blood. 2011;118(21):1748.","journal-title":"Blood"},{"key":"6_CR133","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.21598","volume":"85","author":"RA Mesa","year":"2010","unstructured":"Mesa RA, et al. Phase 1\/-2 study of pomalidomide in myelofibrosis. Am J Hematol. 2010;85:129\u201330.","journal-title":"Am J Hematol"},{"key":"6_CR134","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/archinte.1982.00340210131023","volume":"142","author":"LH Brubaker","year":"1982","unstructured":"Brubaker LH, et al. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Arch Intern Med. 1982;142:1533\u20137.","journal-title":"Arch Intern Med"},{"key":"6_CR135","first-page":"595","volume":"85","author":"F Cervantes","year":"2000","unstructured":"Cervantes F, et al. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica. 2000;85:595\u20139.","journal-title":"Haematologica"},{"key":"6_CR136","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/(SICI)1096-8652(199612)53:4<239::AID-AJH5>3.0.CO;2-Z","volume":"53","author":"V Levy","year":"1996","unstructured":"Levy V, et al. Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. Am J Hematol. 1996;53:239\u201341.","journal-title":"Am J Hematol"},{"key":"6_CR137","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.leukres.2012.02.027","volume":"36","author":"R Tibes","year":"2012","unstructured":"Tibes R, Mesa RA. Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques. Leuk Res. 2012;36:664\u201371.","journal-title":"Leuk Res"},{"key":"6_CR138","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2011.255","volume":"26","author":"A Deshpande","year":"2012","unstructured":"Deshpande A, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia. 2012;26:708\u201315.","journal-title":"Leukemia"},{"key":"6_CR139","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2010.036350","volume":"96","author":"T Hornakova","year":"2011","unstructured":"Hornakova T, et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica. 2011;96:845\u201353.","journal-title":"Haematologica"},{"key":"6_CR140","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3109\/10428194.2011.566952","volume":"52","author":"R Tibes","year":"2011","unstructured":"Tibes R, Mesa RA. Myeloproliferative neoplasms 5\u00a0years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy? Leuk Lymphoma. 2011;52:1178\u201387.","journal-title":"Leuk Lymphoma"},{"key":"6_CR141","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.leukres.2012.04.021","volume":"36","author":"C Cherington","year":"2012","unstructured":"Cherington C, et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res. 2012;36:1147\u201351.","journal-title":"Leuk Res"},{"key":"6_CR142","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11899-011-0107-9","volume":"7","author":"MN Kundranda","year":"2012","unstructured":"Kundranda MN, et al. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? Curr Hematol Malig Rep. 2012;7:78\u201386.","journal-title":"Curr Hematol Malig Rep"},{"issue":"21","key":"6_CR143","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood.V116.21.460.460","volume":"116","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, et al. A phase I\/II study of CYT387, an oral JAK-1\/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms [abstract no. 460]. Blood. 2010;116(21):460.","journal-title":"Blood"},{"issue":"21","key":"6_CR144","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1182\/blood.V118.21.3849.3849","volume":"118","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, et al. An expanded multicenter phase I\/II study of CYT387, a JAK-1\/2 inhibitor for the treatment of myelofibrosis [abstract no. 3849]. Blood. 2011;118(21):3849.","journal-title":"Blood"}],"container-title":["Molecular Diagnosis &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-012-0006-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40291-012-0006-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-012-0006-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T22:28:51Z","timestamp":1714429731000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40291-012-0006-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,29]]},"references-count":144,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["6"],"URL":"https:\/\/doi.org\/10.1007\/s40291-012-0006-3","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,29]]}}}